Literature DB >> 2701210

Pros and cons of intra-arterial chemotherapy.

D J Stewart1.   

Abstract

Pharmacological studies in humans and animals have documented increased local tissue and plasma concentrations of a number of different chemotherapy agents after intra-arterial chemotherapy administration. In addition, animal studies have shown superior therapeutic efficacy using this approach. While some clinical studies of intra-arterial chemotherapy have been negative, others have supported the contention that it is advantageous in some situations. It could potentially help preserve local organ function, palliate, and prolong survival. It would have the potential of increasing cure rates only for tumors that usually kill as a result of localized disease rather than as a result of metastases. On the negative side, it has not been unequivocally proven to be superior to systemic chemotherapy administration, it is technically difficult and expensive, and it can be exceptionally toxic. Further studies are warranted, but for most tumor types, it should still be considered investigational.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2701210

Source DB:  PubMed          Journal:  Oncology (Williston Park)        ISSN: 0890-9091            Impact factor:   2.990


  9 in total

1.  Feasibility study of intraarterial vs intravenous cisplatin, BCNU, and teniposide combined with systemic cisplatin, teniposide, cytosine arabinoside, glycerol and mannitol in the treatment of primary and metastatic brain tumors.

Authors:  D J Stewart; Z Grahovac; H Hugenholtz; V DaSilva; M T Richard; B Benoit; G Belanger; N Russell
Journal:  J Neurooncol       Date:  1993-07       Impact factor: 4.130

2.  Does streaming affect the cerebral distribution of infraophthalmic intracarotid chemotherapy?

Authors:  Ronit Agid; Rina Rubinstein; Tali Siegal; Hava Lester; Felix Bokstein; Roland Chisin; John M Gomori
Journal:  AJNR Am J Neuroradiol       Date:  2002 Nov-Dec       Impact factor: 3.825

3.  Intra-arterial carboplatin and intravenous etoposide for the treatment of metastatic brain tumors.

Authors:  Herbert B Newton; Mary A Slivka; Carol Volpi; Eric C Bourekas; Gregory A Christoforidis; Melissa A Baujan; Wayne Slone; Donald W Chakeres
Journal:  J Neurooncol       Date:  2003-01       Impact factor: 4.130

4.  Brain metastases from fallopian tube carcinoma responsive to intra-arterial carboplatin and intravenous etoposide: a case report.

Authors:  H B Newton; C Stevens; M Santi
Journal:  J Neurooncol       Date:  2001-12       Impact factor: 4.130

5.  Intra-arterial carboplatin and intravenous etoposide for the treatment of recurrent and progressive non-GBM gliomas.

Authors:  Herbert B Newton; Mary Ann Slivka; Carol L Stevens; Eric C Bourekas; Gregory A Christoforidis; Melissa A Baujan; Donald W Chakeres
Journal:  J Neurooncol       Date:  2002-01       Impact factor: 4.130

6.  Intra-arterial carboplatin chemotherapy for brain tumors: a dose escalation study based on cerebral blood flow.

Authors:  T F Cloughesy; Y P Gobin; K L Black; F Viñuela; F Taft; B Kadkhoda; F Kabbinavar
Journal:  J Neurooncol       Date:  1997-11       Impact factor: 4.130

7.  Superselective intraarterial cerebral infusion of cetuximab after osmotic blood/brain barrier disruption for recurrent malignant glioma: phase I study.

Authors:  Shamik Chakraborty; Christopher G Filippi; Tamika Wong; Ashley Ray; Sherese Fralin; A John Tsiouris; Bidyut Praminick; Alexis Demopoulos; Heather J McCrea; Imithri Bodhinayake; Rafael Ortiz; David J Langer; John A Boockvar
Journal:  J Neurooncol       Date:  2016-03-05       Impact factor: 4.130

8.  Intraarterial cisplatin plus intravenous doxorubicin for inoperable recurrent meningiomas.

Authors:  D J Stewart; S Dahrouge; M Wee; S Aitken; H Hugenholtz
Journal:  J Neurooncol       Date:  1995       Impact factor: 4.130

Review 9.  Intra-arterial chemotherapy of primary brain tumors.

Authors:  Herbert B Newton
Journal:  Curr Treat Options Oncol       Date:  2005-11
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.